Clomipramine trial for treatment-resistant persistent genital arousal disorder: a case series

Introduction: Treatment of persistent genital arousal disorder (PGAD), as a chronic and disabling condition, implicates substantial compelling complexities. Methods: In this case series, seven women diagnosed with PGAD who were referred to the Sexual Dysfunction Unit of Psychotherapy Outpatient Clin...

Full description

Saved in:
Bibliographic Details
Published in:Journal of psychosomatic obstetrics and gynaecology 2017-10, Vol.38 (4), p.260-267
Main Authors: Yildirim, Ejder Akgun, Hacioglu Yildirim, Munevver, Carpar, Elif, Sarac, Irmak
Format: Article
Language:English
Subjects:
Adult
Aged
Clomipramine - therapeutic use
Combined Modality Therapy
Female
Humans
Middle Aged
Psychotherapy
Serotonin Uptake Inhibitors - therapeutic use
Sexual dysfunction (biological)
Sexual Dysfunction, Physiological - drug therapy
Sexual Dysfunction, Physiological - psychology
Sexual Dysfunction, Physiological - therapy
Sexual Dysfunctions, Psychological - drug therapy
Sexual Dysfunctions, Psychological - psychology
Sexual Dysfunctions, Psychological - therapy
treatment interventions
Treatment Outcome
Turkey
Women's sexuality
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: Treatment of persistent genital arousal disorder (PGAD), as a chronic and disabling condition, implicates substantial compelling complexities. Methods: In this case series, seven women diagnosed with PGAD who were referred to the Sexual Dysfunction Unit of Psychotherapy Outpatient Clinic of Bakirkoy Research and Training Hospital for Psychiatry, Neurology, and Neurosurgery, Istanbul, Turkey between 2006 and 2009 were included. All patients were previously resistant to other antidepressants, antipsychotics and antiepileptics. The additional details of PGAD onset, frequency, type and duration of arousal, previous pharmacological interventions, and maximum and maintenance doses of clomipramine were recorded. Results: All patients achieved a substantial symptomatic improvement with clomipramine within the follow-up period of 2-9 years. Discussion: Based on our study results, we recommend clomipramine in combination with psychotherapy as the treatment of choice in PGAD and to be used before any invasive procedure such as electroconvulsive therapy (ECT) or surgery.
ISSN:0167-482X
1743-8942
DOI:10.1080/0167482X.2017.1296427